

BP-50650

Voxalatamab - Anti-Human CD3/PSMA Bispecific Antibody

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer.

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Human IgG4 (S228P) kappa
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	SP34-2/OKT3
Target	Anti-human PSMA and CD3
Purity	>99%
Molecular Weight	144.68 kDa
CAS Number	2411871-58-2
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.